Canaccord Genuity Maintains Buy on Pacific Biosciences, Lowers Price Target to $3
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Kyle Mikson maintains a Buy rating on Pacific Biosciences (NASDAQ:PACB) but lowers the price target from $3.5 to $3.

August 08, 2024 | 10:46 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Canaccord Genuity analyst Kyle Mikson maintains a Buy rating on Pacific Biosciences but lowers the price target from $3.5 to $3.
The Buy rating suggests continued confidence in the company's long-term prospects, but the lowered price target indicates some short-term concerns or adjustments in valuation. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100